Latest news

• Roche snags pair of FDA breakthrough designations

  drug. In J-ALEX - conducted by Roche's Japanese subsidiary Chugai - Alecensa reduced the risk of disease-worsening or death by 66% compared to Xalkori. ... First launched in Japan for 2005 for Castleman's disease - and subsequently getting the green

• Roche wins early use RA approval for RoActemra in Europe

  Adds to existing indications in arthritis and Castleman’s disease. Roche's arthritis brand RoActemra (tocilizumab) has widened its European licence, winning a new EU indication to treat early rheumatoid arthritis. ... The study showed patients on the

• EC approves Janssen rare blood disorder drug

  Sylvant available to treat multicentric Castleman's disease. Janssen's Sylvant this week became the first drug approved in Europe to treat the rare blood disorder multicentric Castleman's disease (MCD). ... rare and challenging disease and further

• FDA approves Janssen drug for rare Castleman’s disease

  Sylvant approved to treat lymphoma-like condition. The US FDA has approved a new drug to treat a rare cancer-like condition known as multicentric Castleman's disease. ... It is also designated an orphan drug due to the rarity of multicentric Castleman's

• EMA backs Janssen rare disease drug for approval

  Castleman's disease treatment Sylvant wins CHMP recommendation. J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe. ... Castleman's disease is a rare disorder characterised by